Year: 2024

Optimizing Cell & Gene Therapies with Multi-Omic Sequencing

Heather Stark, the Global Segment Manager at Oxford Nanopore Technologies, introduced the webinar “Enhancing Cell and Gene Therapy Success with Multi-Omic Sequencing: The Oxford Nanopore Advantage.” Start covers biopharma and explained how nanopore sequencing works. They explained that there are several end-to-end workflows for synthetic biology, including plasmid, AAV, amplicon, and mRNA IVT sequencing. Clark […]
Read more

BugSeq’s Innovative Approaches to Virus Detection

Tonight I continued watching the ONT webinar on advances in genomic profiling of respiratory viral pathogens. The second speaker was Nick Gauthier from BugSeq. The title of their session was “Translating metagenomics to the clinic.” The BugSeq team is working to develop clinical metagenomic pathogen agnostic approaches. BugSeq started working on an ONT mNGS platform […]
Read more

Rapid Viral Genome Sequencing: Highlights from a Recent Webinar

I watched the webinar tonight facilitated by Anna Maria Niewiadomska, Global Market Segment Manager in Public Health at Oxford Nanopore Technologies. They first spoke about using ONT for microbiology and infectious disease work. The turnaround time with the rapid library prep was one feature that Niewiadomska highlighted, as well as the real-time analysis and read-length […]
Read more

Challenges in Clinical Sequencing Techniques

Tonight, I continued watching the Oxford Nanopore Technologies London Calling 2024 expert panel on “Building a rapid, targeted, and responsive infectious disease system.”Aaron Pomerantz, the Global Segment Marketing Associate Director at ONT, facilitated the session. All panelists were invited to the stage after doing brief introductions. Rahul Batra from Guy’s and St. Thomas’ NHS Foundation Trus […]
Read more

Building Effective Multi-Disease Surveillance Systems

Tonight, I started watching the Oxford Nanopore Technologies London Calling 2024 expert panel on “Building a rapid, targeted, and responsive infectious disease system.”Aaron Pomerantz, the Associate Director of Global Segment Marketing at ONT, helped facilitate the session. Dr. Ines Hassan from the Tony Blair Institute for Global Change started. Hassan helps encourage the development and […]
Read more

Understanding the MinION Mk1D: Innovations for Microbiology

Tonight, I continued watching the session on the MinION Mk1D. The second speaker of the webinar was James Platt, the Director of Sequencing Platforms with Oxford Nanopore Technologies (ONT). They described the details of the MinION’s history. The Mk1D was rebuilt, including USB-C connectivity, Peltier module temperature control, and LED run status indicators. A comparison of the Mk1B […]
Read more

Testing the MinION Mk1D in Alaskan Conditions

Tonight, I watched Devin M. Drown from the University of Alaska Fairbanks present on “Testing the MinION Mk1D in Alaska.” Drown is an Associate Professor and Faculty Director of the Institute of Arctic Biology Genomics Core. Drown is passionate about training, including doing MinION hackathons. Drown, like me, was excited to test the device. They […]
Read more

Transforming Cancer Care with Nanopore Sequencing

I continued watching the “Nanopore Sequencing Ultra Rich Data for Cancer Research” webinar. It featured Sayonika Mohanta, the Market Segment Manager for Methylation with Oxford Nanopore Technologies (ONT). Mathilde Fiser from the Curie Institute presentation had the title “Transforming Cancer Care: Redefining Cancer Characterization and Predisposition Insights through Nanopore Sequencing.” Fiser explained that the identification of germline alterations […]
Read more

Nanopore Sequencing: Transforming Cancer Research with Rich Data

The “Nanopore Sequencing Ultra Rich Data for Cancer Research” webinar featured Sayonika Mohanta, the Market Segment Manager for Methylation with Oxford Nanopore Technologies (ONT). Mohanta began by emphasizing that cancer research requires multimodal approaches. The example they presented was the use of WGS of cell-free or circulating tumor DNA combined with proteomics and methylation. They […]
Read more

Advancements in Precision Oncology: Key Insights from London Calling 2024

Tonight, I continued watching a session from the London Calling 2024 Clinical & Biopharma Day. The expert panel’s title was “Precision oncology: driving better outcomes for patients, health systems, and populations.” Olivier Lucas, the Director of Oncology with Oxford Nanopore Technologies (ONT), moderated the discussion. The audience asked the panelists questions about sensitivity and risk determination. William Stanford from […]
Read more
Press ESC key to close search